Highest-materiality recent filing
Equity plan amended to increase authorized shares by 500,000 to 3,175,000; approved with 994,315 votes for.
TAO Synergies raises $11M in private placement; terminates Alkon agreement; appoints Vice-Chairman
Sold 11,000 Series E convertible preferred shares ($1,000 stated value) and warrants for 1.375M common shares at $8.00; $11M gross proceeds.
Joseph Jacks, co-founder/CEO of Latent Holdings and early Bittensor pioneer, engaged as advisor to digital asset treasury strategy led by James Altucher.
TAOX shareholders approve 20%+ share issuance and 2M-share equity plan increase
Special meeting held Aug 6, 2025; 567,847 shares (35.23%) represented, quorum achieved.
TAO Synergies accumulates 42,111 Bittensor (TAO) tokens as part of DeAI treasury strategy
As of Aug 5, 2025, holds 42,111 TAO tokens acquired via purchases and staking.
TAO Synergies acquires $10M in TAO tokens, becoming largest public pure play holder
Acquired 29,899 TAO tokens for $10M at avg ~$334/token as of July 17, 2025.
Synaptogenix rebrands to TAO Synergies, shifts to AI-focused crypto treasury with staking
Name changed to TAO Synergies Inc. effective June 26, 2025; ticker to change from SNPX to TAOX on July 1.
Synaptogenix buys TAO, hires BitGo for custody/staking, begins staking yield
Initial purchase of TAO under crypto treasury strategy focused on AI and machine learning.
Synaptogenix launches crypto treasury strategy focused on Bittensor TAO, raises $5.5M
Plans initial $10M acquisition of TAO tokens (over 2x market cap); long-term target of $100M.
Synaptogenix forms special committee to explore strategic alternatives; ends Bryostatin-1 MS trial
Board formed special committee to explore strategic opportunities; $19.6M cash and ~1.3M shares outstanding as of Sept 30, 2024.
Elected directors Silverman (369,569 for) and Singer (367,990 for); broker non-votes 368,218.
Synaptogenix replaces auditor: Morison Cogen resigns, Stephano Slack engaged for FY2024
Morison Cogen resigned Sept 30, 2024 due to exit from public company audit services.
Synaptogenix raises $5M via Series C Convertible Preferred and warrants
Closed private placement of Series C Preferred (convertible at $4/share) and warrants for aggregate gross proceeds of $5M.
Gross proceeds of $5.0M from sale of 5,000 shares of Series C convertible preferred stock (stated value $1,000) and warrants.
Synaptogenix extends Series B Preferred maturity date to Sept 9, 2024
Filed Certificate of Amendment to Series B Convertible Preferred Stock on Sept 3, 2024.
Amendment No. 3 to Offer Letter extends CEO term to December 7, 2024.
Synaptogenix effects 1-for-25 reverse stock split to regain Nasdaq minimum bid price compliance
Reverse split effective 5pm ET April 4, 2024; shares trade split-adjusted on April 5 under SNPX.
Stockholders authorized reverse stock split at ratio between 1:8 and 1:25, at Board's discretion.
Synaptogenix invests up to ~$3.44M in Cannasoul Analytics for preferred shares and convertible notes
Initial investment: $562,770 for 12,737 Series A preferred shares (5% stake) at $44.1550/share.
Filed Certificate of Amendment on Sept. 22, 2023, modifying Series B Convertible Preferred Stock terms.
Synaptogenix partners with Cleveland Clinic for Phase 1 Bryostatin-1 trial in multiple sclerosis
Agreement with Cleveland Clinic to conduct Phase 1 trial of Bryostatin-1 in multiple sclerosis; IND submission to FDA planned.
Synaptogenix extends CEO Alan Tuchman's employment through June 7, 2024
CEO Alan Tuchman's employment term extended to June 7, 2024 with automatic monthly renewals.
Synaptogenix receives Nasdaq delisting notice for bid price below $1.00
Nasdaq notified Synaptogenix on April 24, 2023 that its stock failed to maintain minimum $1.00 closing bid price for 30 consecutive days.
Special meeting on April 14, 2023; 2,923,975 shares (40.23%) represented, quorum present.
Synaptogenix cash balance ~$37.5M as of Dec. 31, 2022
Cash and cash equivalents of approximately $37.5 million as of December 31, 2022.
Synaptogenix special meeting adjourned without business, reconvene date TBD
Special meeting held Feb 16, 2023 was adjourned with no business conducted.
Synaptogenix reduces stockholder meeting quorum from majority to one-third
Board approved amendment to Bylaws, effective December 27, 2022.
Synaptogenix Phase 2 trial of Bryostatin-1 fails to meet primary endpoint in advanced Alzheimer's
Primary endpoint: change in SIB total score at week 28; Bryostatin-1 1.4 pts vs placebo 0.6 pts, not statistically significant.
Synaptogenix creates Series B Convertible Preferred, closes $15M private placement
Issued Series B Convertible Preferred Stock with initial conversion price of $7.75 per share.
Gross proceeds of $15M from sale of Series B convertible preferred stock (initial conversion at $7.75/share) and warrants.
Stockholders approve amendment to 2020 Equity Incentive Plan, doubling authorized shares to 1.375M
At Oct 11 annual meeting, 56.32% of shares represented; all three proposals passed.
Synaptogenix dismisses Friedman LLP, appoints Morison Cogen as auditor effective Sept 1, 2022
Audit committee elected not to continue with Friedman LLP as independent auditor effective Sept 1, 2022.
George Perry resigns from Synaptogenix board, retains advisory role
Perry resigned from board and all committees effective September 30, 2021.
Synaptogenix grants 485,000 RSUs to directors and officers for spin-off and up-listing efforts
RSUs awarded to 8 individuals (including CEO, CFO, directors) totaling 485,000 shares.
On June 8, 2025, Dr. Alan J. Tuchman resigned as Chief Executive Officer and director of the Company, effective June 8, 2025. Dr. Tuchman will serve as Chief Medical Officer of the Company.
On June 4, 2025, Dr. Daniel L. Alkon resigned as an officer, director and Chief Science Officer of the Company to become a consultant working with the Company’s newly established Bryostatin Development Committee
On June 6, 2025, Mr. Joshua Silverman was appointed as Executive Chairman of the Company’s board of directors and in consideration of his new role, Mr. Silverman will be paid a monthly salary of $30,000 per month.
On September 30, 2021, George Perry resigned from his position as a member of the board of directors (the “Board”) of Synaptogenix, Inc. (the “Company”) and as a member of all committees of the Board on which he serves.
Max materiality 0.90 · Median 0.60 · Most common event other_material